Product Description
Cilobradine (CIL, DK-AH269), an inhibitor of hyperpolarization-activated cation current (Ih), has been observed to possess pro-arrhythmic properties. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32244431/)
Mechanisms of Action: INA Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02264015 |
NCT02264015 | P1 |
Completed |
Healthy Volunteers |
2004-05-01 |
2024-11-27 |
||
NCT02264041 |
NCT02264041 | P1 |
Completed |
Healthy Volunteers |
2004-04-01 |
2019-03-20 |
||
NCT02264002 |
NCT02264002 | P1 |
Completed |
Healthy Volunteers |
2003-11-01 |
2019-03-20 |
Treatments |